Aro Biotherapeutics is a biotechnology company. The company specializes in creating Centyrin-based therapeutic candidates that modulate gene targets in disease tissues. Aro Biotherapeutics collaborates with industry partners to apply its Centyrin technology for the targeting of therapeutics across various diseases. It was founded in 2018 and is based in Philadelphia, Pennsylvania.

Notch Therapeutics provides early-stage biotech solutions focusing on cellular immunotherapies, particularly for cancer treatment. It specializes in creating therapeutic T cells from pluripotent stem cells using a technology platform that allows for precision control of notch signaling. Its products are designed to address the underlying biology of complex diseases and offer a uniform and unlimited supply of therapeutic cells. The company was founded in 2018 and is based in Vancouver, Canada.

Virogin Biotech is a biotechnology company focused on the development of oncolytic virotherapies. The company specializes in creating drugs aimed at treating patients with medical need, particularly in the realm of cancer. It was founded in 2015 and is based in Vancouver, British Columbia.

Novocure is an oncology company that focuses on the treatment of aggressive forms of cancer. The company develops and commercializes its cancer therapy, Tumor Treating Fields (TTFields), which is used for adult patients with glioblastoma and malignant pleural mesothelioma. Novocure conducts clinical trials for other cancers, including brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and gastric cancer. It was founded in 2000 and is based in Root, Switzerland.

Genmab operates as an international biotechnology company focused on developing antibody therapeutics for the healthcare industry. The company's main offerings include a range of antibody-based treatments such as bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators. Genmab's products are primarily targeted towards the oncology sector, with a goal to address the needs of people with cancer and other serious diseases. It was founded in 1998 and is based in Valby, Denmark.

Juno Therapeutics offers a clinical-stage pipeline of immunotherapies. It targets cell surface antigens that are expressed in cancer cells and offers high-affinity T cell receptor (TCR) technology to detect alterations in intracellular proteins present in tumor cells. The company was founded in 2013 and is based in Seattle, Washington. In March 2018, Juno Therapeutics was acquired by Celgene.